Correvio Pharma Corp. (NASDAQ:CORV)

Cardiome Pharma Corp., a research-based biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on ion channel and cardiovascular research. It also has a collaboration and license agreement with Merck & Co., Inc. for the development and commercialization of BRINAVESS. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Last updated March 6, 2013